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Abstract
Carriers of a pathogenic germline mutations in the PTEN gene, a well-known tumor suppressor gene, are at
increased risk of multiple benign and malignant tumors, e.g. breast, thyroid, endometrial and colon cancer. This is
called PTEN Hamartomous Tumor Syndrome (PHTS). PHTS patients may also have an increased risk of
immunological dysregulation, such as autoimmunity and immune deficiencies. The effects of PTEN on the
immune system have been studied in murine knockout models demonstrating that loss of PTEN function leads to
dysregulation of the immune response. This results in susceptibility to autoimmunity, impaired B cell class
switching with subsequent hypogammaglobulinemia. Additionally, a decreased ability of dendritic cells to prime
CD8+ T cells was observed, leading to impaired tumor eradication. Immune dysfunction in PHTS patients has not
yet been extensively studied but might be a manageable contributing factor to the increased cancer risk in PHTS.
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Introduction
The role of the immune system in carcinogenesis and cancer
progression has been widely established, but an association between
hereditary tumor syndromes and immunological dysfunction has not
yet been demonstrated. Hereditary tumor syndromes are caused by
germline mutations in tumor suppressor genes or proto-oncogenes,
one of such tumor syndromes is PTEN hamartoma tumor syndrome
(PHTS). PHTS is an autosomal dominant tumor syndrome, caused
by loss of function mutations in the phosphatase and tensin homolog
gene (PTEN). PTEN is a negative regulator of the PI3K/Akt pathway,
thereby acting as a tumor suppressor gene. Through the PI3K/Akt
pathway, PTEN has a regulating effect on cell proliferation, cell
metabolism, cell survival and angiogenesis [1–3].
PHTS is a collective term that replaces previously used syndrome
names, such as; Cowden syndrome, Bannayan-Riley-Ruvalcaba
syndrome and Proteus-like syndrome. It is associated with an
increased risk of benign and malignant tumors of the breast, thyroid,
endometrium, colon and other forms of tumors. Additionally, PHTS
patients may have many different features ranging from macro-
cephaly, developmental delay and autism specter disorders to benign
skin and organ lesions such as trichilemmomas and dysplastic
gangliocytoma [4–7]. The current estimate is that 1 in 200,000
individuals has PHTS. However, because several PHTS features are
quite common in the general population, such as benign lesions of the
breast uterus and skin, these patients may not have been recognized as
PHTS. This means that the incidence of PHTS in the general
population may be higher than the earlier estimates [8]. Clinical
characteristics of PHTS show high penetrance and it is estimated that
at age 30, nearly 100% of germline PTEN mutation carriers exhibit
some features associated with PHTS. De novo mutations make up for
10–40% of diagnosed cases [4].
Involvement of the immune system in carcinogenesis is widely known
and accepted. During cancer development, regulatory cellular processes
are lost and genetic alterations accumulate [9]. This leads to the
expression of neoantigens by cancer cells that can eventually be
recognized by the immune system as foreign and consequently elicit a
CD8+ T cell mediated response [10]. In recent years, evidence of
immune dysregulation in PHTS patients has emerged with the
publication of small case series as well as more extensive cohorts
[11–17]. Nevertheless, a possible relationship between immune
dysregulation and cancer risk has not been established in PHTS. This
review aims to elaborate on known immunological phenomena in PHTS
individuals and PTEN knockout mice and to identify directions for
future research. We hypothesize that intervening in the immunological
dysregulation may lead to new treatment options for PHTS patients.
Immunological Phenomena in PHTS Patients
In spite of the heterogeneous phenotypes of PHTS individuals, the
immunological symptoms reported in literature seem quite consis-
tent. Recurring upper respiratory tract infections are reported in
multiple case reports and case series [11,12,18]. In one of these case
reports, one individual developed a skin manifestation compatible
with a reactive cutaneous lymphocytic vasculitis that fully resolved
after tonsillectomy [12]. A larger retrospective study with 34 PHTS
patients, did not report any susceptibility to infections [14].
In all of the cases with recurrent upper respiratory tract infections,
hyperplasia of the adenoids and/or tonsils were present [11,12,18]. In
one individual diagnosed with PHTS, extreme pharyngeal papilloma-
tosis and tonsillar hypertrophy triggered by Epstein–Barr viral infection
caused extensive airway obstruction necessitating tracheotomy. Obser-
vations from biopsies revealed only benign lymphofollicular hyperplasia
without malignancy. The son of this individual carried the same PTEN
mutation and presented himself at the age of 4 with sleep apnea due to
extensive tonsillar enlargement. Pathological examination revealed
papillomatous changes with lymphofollicular hyperplasia, similar to the
findings in the father's case [16].
Lymphoid hyperplasia in PHTS patients is not restricted to
adenoid and tonsillar lymphoid tissue, Tsujita et al. used PET-scans
to determine lymphoid hyperplasia in two PHTS individuals and
demonstrated increased cervical and abdominal lymph nodes [18].
Gastrointestinal polyps with follicular lymphoid hyperplasia has been a
reported finding in independent case series. In 34 PHTS patients, 16
(50%) had gastro-intestinal lymphoid hyperplasia, located in the colon
and rectosigmoid without signs of mucosa-associated lymphoid tissue
(MALT) lymphoma. Investigation of MALT tissue in controls and
PHTSpatients revealed reduced apoptosis and increased proliferation of
CD10+ pre-B cells. There were no differences detected between control
and PHTS T cell populations [14]. In a more recent publication, 7 out
of 12 (58%) PTEN patients with confirmed PTEN mutations had
hamartomous polyps with hyperplastic lymphoid follicles [19]. It must
be stressed, however, that polyposis is a possible feature of PHTS that
has not been studied extensively and large studies have not yet been
published.
Abnormalities in the humoral response of the adaptive immune
system have also been reported. Hypogammaglobulinemia has been
reported in several publications [11,20]. Further analysis of the
immunoglobulin subtypes in PHTS patients show impaired class
switch recombination (CSR) leading to a disrupted IgG and IgA
subclass distribution with increased IgG1 and decreased IgG2
concentrations. Similar results were described for IgA [20]. In a
larger study, hypogammaglobulinemia was not observed in 34 PHTS
patients, although PHTS immunoglobulin levels were reported to be
in the lower level of normal [14]. In one case report of a 5- year old
boy, within 15 months long-term humoral response to Haemophilus
Influenzae B and pneumococcal vaccination declined to nearly
baseline levels [11]. Further study of this phenomenon is warranted.
Lymphopenia has also been reported in a few case series [11–13,18].
Increases in the absolute number of peripheral transitional B cell subsets
combinedwith a reduction of circulating CD4+ T cells with subsequent
inversion of the CD4+/ CD8+ ratio is shown in multiple studies
[13,14,20]. The increase of transitional B cells appears to be more
pronounced in patients with hypogammaglobulinemia [20].
In patients with PHTS, dysregulation of the immune system is also
reflected by hyperinflammation leading to an increased incidence of
disorders. In 34 patients described by Heindl et al., 7 (21%) displayed
autoimmune disorders such as autoimmune lymphocytic thyroiditis
and autoimmune haemolytic anemia [14]. More recently, autoim-
munity related phenomena were seen in 27% of 79 PHTS patients,
including thyroiditis, colitis, celiac disease, haemolytic anemia and
pernicious anemia [13]. These results imply that autoimmunity may
be a feature of PHTS and therefore, it warrants further investigation.
An overview of the immunological features previously observed in
PHTS patients is depicted in Table 1.
In some primary immunodeficiency syndromes, the pathway in which
PTEN has a function, the PI3K/Akt1/mTOR pathway, is known to be
upregulated and is a well-known causal factor of immunodeficiency.
Activated PI3Kδ syndrome (APDS) leads to a plethora of immunological
phenomena such as recurrent sinopulmonary infections, inability to clear
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viral infections, benign lymphadenopathy, and autoimmune diseases
[21,22]. It is caused by gain-of-function mutations in the phosphoinosi-
tide 3 kinase (PI3Kδ) gene, a leukocyte specific subunit of PI3K [23,24].
Loss of function in the downregulating gene PIK3R1, coding for the
regulatory PI3K subunit p85α, has also been reported to cause immune
deficiencies [25]. Symptoms correlate with the symptoms observed in
PHTS patients, although APDS symptoms tend to be more severe. The
clinical similarities and implication of the same pathway underscore the
involvement of PTEN in immune system function.
PTEN and the Immune System
In cancer development failure of the immune system to recognize and
destroy malignant cells is mandatory for tumor survival. Tumors can
employ numerous tactics to escape immune surveillance [26,27]. By
modulating their own micro-environment, tumors can evade the
immunological anti-tumor response by the secretion of immunosup-
pressing cytokines and chemokines. Information on this so-called
tumor micro-environment (TME) in PTEN deficient organisms
comes almost exclusively from murine models, as gathering sufficient
human PHTS related tumors is complex due the fact that PHTS is a
rare disease. The interplay between different cells of the immune
system has not been studied extensively in PTEN −/− mice.
Natural Killer Cells
Natural killer (NK) cells have functions in the finding and
destruction of infected, foreign or malignant cells [28,29]. The role of
PTEN and the PI3K/Akt pathway in NK function and maturation
has been a point of interest for some time [30–33]; Briercheck and
colleagues reported that an NK cell lineage specific deletion of PTEN
gives rise to NK cells with increased cytolytic function [34].
Additionally, the migration of NK cells towards distal tumors in
PTEN-deleted NK cells in mice is impaired and the migration of
NK cells from the bone marrow to the bloodstream is increased.
Tumor cells that were introduced into the peripheral bloodstream
were cleared more effectively than in wild type mice [35]. If these
findings are translatable to human PHTS physiology, this would
imply a decreased ability of NK cells to target cancer cells in tissue and
thus an increased cancer risk.
Macrophages
Macrophages are important players in the TME, and in certain
tumors as much as 50% of tumor mass can be tumor associated
macrophages (TAMs) [36]. Infiltration of tumors by TAMs is
generally associated with poorer prognosis [37–39]. To describe their
functional programming and activation status, macrophages have
classically been divided in the proinflammatory M1 type macrophage
and the anti-inflammatory, proliferation supporting M2 type. M1
macrophages are equipped for the “eradication phase” of the immune
response, while M2 macrophages are essential in the tissue healing
process [40]. Nevertheless, macrophages are characterized by a high
functional plasticity and therefore a wide range of variety with respect
to their pro- and anti-inflammatory activity is observed. Studies in
myeloid PTEN deficient mice report an increase in M2-like
peritoneal and bone marrow-derived macrophages with an increased
arginase I activity [41]. Importantly, the TAMs infiltrating the TME
of many malignant tumors, including breast cancers which are
prevalent in PHTS patients, show a preponderance of M2-like
macrophages that are regarded as tumor promotors [42]. Increased
arginase production by TAMs can lead to impaired T cell function
due to arginine depletion in the TME, thereby reducing immune
surveillance [41]. Moreover, the PI3K/AKT/mTOR is one of the key
regulators of the cell metabolism. Emerging evidence indicates that
functional reprogramming of macrophages/TAMs is highly depen-
dent on changes in the immune cell metabolism linked to activation
of the Akt/mTOR pathway, which is in turn essential for reshaping
the epigenetic landscape and functional program of the cell [43–47].
Myeloid Derived Suppressor Cells (MDSCs)
MDSCs comprise a heterogeneous group of immune cells with
suppressive functions in chronic inflammatory conditions [48,49].
Infiltration of tumors with MDSCs is associated with attenuated T
cell function and decreased effect of immune checkpoint inhibition
therapy (ICI) [50–52]. By selectively inhibiting the myeloid specific
PI3K in murine models, De Heneau et al. restored sensitivity for ICI
in tumors with high MDSC infiltration [53]. Sensitisation to ICI was
also achieved in head and neck cancers by selective inhibition of
PI3Kδ and PI3K isoforms [54]. With PTEN as a negative regulator
of the PI3K/Akt pathway, (partial) loss of PTEN function may
contribute to MDSC dependent suppression of T cells and inhibit
tumor surveillance.
Dendritic Cells
Dendritic cells (DCs) are the professional antigen presenting cells and
have a pivotal role in the priming of the adaptive immune system [55].
Dysfunction of DCs could theoretically lead to decreased tumor immune
surveillance through impaired activation of CD8+ cytotoxic T cells. In a
PTEN−/− myeloid lineage murine model, PTEN deletion led to an
increased colon cancer tumor load and decreased survival. However, an
increased number of CD8α+ DCs was found in the spleen. CD8α+
cross-presentingDCs are a uniqueDC subset specialized in cross-priming
Table 1. Immunological clinical features in PHTS patients.
Study (number of
cases reported)
Described clinical features (number of cases with features)
Heindl et al.(34) [14] -lymphoid hyperplasia (26/34)
-Autoimmunity (11/34)
Browning et al. (2) [11] -Recurrent (upper) respiratory tract infections (2/2)
-Panhypogammaglobulinemia (1/2)
-Decreased long term antibody response to specific vaccines (1/2)
-Lymphoid hyperplasia (2/2)
-Increased amount of transitional B cells
Driessen et al.(9) [20] -Hypogammaglobulinemia(3/9)
-Increased absolute number of transitional B cells
-Affected class switch recombination, increasing IgG1, and
decreasing IgG2
Mauro et al.(1) [12] -Recurrent upper respiratory tract infections
-Reactive cutaneous lymphocytic vaculitis
-Lympohopenia
Sharma et al.(2) [16] -Recurrent upper respiratory tract infections in childhood (2/2)
-Lymphoid hyperplasia (2/2)
Tsujita et al. (4) [18] -High serum IgM (1/4)
-Recurrent pulmonary opportunistic infections(2/4)
-Lymphopenia (1/4)
-CD4+/CD8+ ratio inversion (1/4)
-Lymphoid hyperplasia(2/4)
Shaco-Levy et al. (12) [19] -Hamartomas with lymphoid follicles 7/12
-Juvenile hamartoma inflammatory intestinal polyps(12)
Boccone et al. (1) [17] -Lymphoid hyperplasia
Chen et al. (79) [13] -Lymphoid hyperplasia (18/79)
-Autoimmunity (21/79)
-Significant reduction of peripheral blood lymphocytes
-Increased number transitional B-cells
-CD4+/CD8+ ratio inversion
Autoimmunity includes Hashimoto's thyroiditis and autoimmune haemolytic anemia.
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of CD8+ cytotoxic T cells and essential for tumor immune-surveillance
[56]. However, in myeloid PTEN−/− mice this cross-priming of
exogenous antigens was deficient. If these findings are translatable to
PHTS, deficient priming ofCD8+ cytotoxic T cellsmay lead to decreased
tumor cell killing activity, promoting tumor growth. Additionally,
PTEN−/− DCs with increased programmed death-ligand 1(PD-L1) and
PD-L2 expression were observed. These molecules are known to induce
anergy in T cells at ligation [57], providing an additional means for the
tumor to escape surveillance.
B Cells
B cells are vital for mounting a humoral response against infection
and tumors. By recognition of (neo)antigens they can produce
antigen specific immunoglobulins. In B cell-specific PTEN−/− mice,
B cells show increased proliferation and decreased apoptosis in the
marginal zones of the spleen. Additionally, they have an increased
number of peritoneal B cells [58]. These cells produce polyreactive
IgM that can react weakly to autoantigens [59]. A deficient class
switch recombination was observed in another B cell specific PTEN−/−
mouse model, with decreased IgG and IgA levels and a fourfold increase
in IgM [60]. Dysfunction of a B cell antibody response leads to
decreased tumor surveillance and an increase in peritoneal B cells could
result in autoimmune disease.
T cells
The role of T cells in counteracting tumor growth by recognition
of tumor-expressed antigens and subsequent activation of effector T
cells has been widely established [61,62]. The PI3K/Akt pathway has
a central role in T cell development [63]. In thymocyte restricted
PTEN−/−, CD3 −/− mice models, thymocytes missing the functional
β-chain receptor were not adequately removed during β-selection [64].
The failure to induce apoptosis in these TCRβ- cells could explain
lymphoid hyperplasia in PHTS patients. Lymphoid hyperplasia and
autoimmunity was also demonstrated in PTEN+/− mice and was
attributed to a decreased response to CD95 (Fas) induced apoptosis
[65]. Binding to the Fas receptor is a major pathway for CD8+ cells to
induce cell death in tumor cells. Decreased response to Fas-induced
apoptosis is often seen in cancer, promoting tumor growth [66].
In T helper (Th) cell specific PTEN knockout mice, Th cells show
an improved stimulatory function and increased excitability by sole
TCR activation. Production of proinflammatory IL-2 by these
PTEN −/− T helper cells, and proliferation, is increased [63,67].
Although not reported in all studies with T cell specific knockout
models, the downside of this increased immune response is the loss of
self-tolerance and the induction of auto-reactive T cells [68]. The
pathophysiological link between autoimmunity remains largely
unclear, but autoimmune disease is associated with increased cancer
risk [69–71]. The increased proliferation of T cells in T cell specific
murine knockout models does not apply to the Th17 subset, Th17
cells are associated with autoimmune disorders such as arthritis.
Downregulation of IL-2 by PTEN is required for Th17 cells to
develop. Loss of PTEN reduces severity of Th17-associated
autoimmunity disorders [72]. In antigen presenting cells specific
PTEN −/− mice, there was a marked decrease in autoimmune arthritis
and autoimmune encephalomyelitis. IL-17 and IL-22 production was
also reduced compared to wild-type mice. Direct administration of
arthritogenic serum, thereby circumventing the adaptive immune
response, did not lead to a diminished phenotype. Most likely, in
mice, PTEN is essential in antigen presenting cells to induce
functional programming towards Th17 cell development [73,74].
Figure 1. Overview of effect of loss of PTEN on the murine immune system.
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CD4+ FoxP3+ regulatory T cells (Tregs) have an important role in
the creation of an immunologically suppressed tumor environment.
Tumors actively recruit Tregs to create an immunosuppressive TME.
The ablation of Tregs in mice drastically decreases tumor load that may
come at a price of lethal autoimmunity [75,76]. In tumors, Tregs
maintain their immunosuppressive phenotype by interaction with the
immunoregulatory enzyme indoleamine 2,3,-dioxygenase (IDO) (over)
expressed in tumor cells and in immune cells often present in the TME,
such as DCs [77]. Downregulation of the Akt pathway is important for
Tregs to maintain stability. Consequently, PTEN was shown to be an
important regulator of Treg function [77]. In Treg specific PTEN
knockout mice, phosphorylation of Akt was increased after IDO
stimulation leading to a switch in phenotype from Tregs to
hyperinflammatory ex-Tregs. As a result, proinflammatory cytokines
such as IL-2 and IL-17 were expressed in the TME and facilitated an
effective anti-tumor response. This suggests that loss of PTEN in Tregs
induces an immunogenic TME [77]. Other studies have also
demonstrated this effect in murine Foxp3+ PTEN−/− models [78,79].
A recent study in PHTS individuals, using biopsies ofmucosa associated
lymphoid tissue, shows that Tregs have a normal phenotype. Suggesting
that residual PTEN activity in PHTS is sufficient to sustain the
immunosuppressive Treg phenotype or that there is compensatory
phosphatase activity [13].
The effects of PTEN deletion on the adaptive immune system are
well documented in mouse models (Figure 1). These models show
changes to B- and T cells that can result in hypogammaglobulinemia
and autoreactivity. Changes to the TME in Treg PTEN−/− mice
demonstrate the important regulatory role PTEN has in regulating
the anti-cancer immune response.
PTEN-Deficient Tumors
Limited data is available on the immune cell populations in PTEN-
deficient tumors. Peng and colleagues report that human melanoma
samples lacking PTEN contain less tumor infiltrating lymphocytes
and achieve less tumor reduction with anti-PD1 antibodies compared
to PTEN-expressing tumors [80,81]. Similar results were reported in
a case report of a female with metastatic uterine leiomyosarcoma who
achieved near total remission after anti-PD1 monotherapy. There was
one treatment resistant lesion which was removed surgically. The
resistant lesion showed post treatment biallelic PTEN mutations and
significant up-regulation of immunomodulatory molecules such as
VEGF and CCL2 was observed in PTEN null tumors [80]. VEGF
has been known to contribute to an immunosuppressive TME by
recruiting MDSCs, Tregs and immature DCs [82]. These data show
that PTEN deletion in tumors may lead to an immunotolerant TME
by the inhibition of lymphocyte infiltration and the upregulation of
immunomodulatory molecules.
Conclusion and Perspective
Current studies suggest that immune dysregulation is one of the
features of PHTS. This dysregulation is reflected in autoimmune
disorders, lymphoid hyperplasia, hypogammaglobulinemia and
changes in T- and B- cell subsets. The role of immune dysregulation
in carcinogenesis in PHTS patients has not yet been extensively
explored. The effects of PTEN-loss have almost exclusively been
investigated in mouse knockout models. In murine PTEN knockout
models, PTEN-null myeloid cells show dysfunction that could be
conducive to an increased cancer risk and a less immunogenic TME.
In these mouse models, the effect of different cell types carrying
PTEN mutations interacting with each other cannot be studied
adequately. Additional models need to be developed to study the
effect of PTEN mutations on human physiology (e.g. organoids).
Targeting dysfunctional immune cell types could lead to new
treatment strategies for cancer in PHTS patients. A viable candidate
cell type to target could be the CD141+ DC subset, improving tumor
antigen cross presentation to CD8+ T cells [83]. Tumor character-
istics, such as up-regulated VEGF expression, can also be a treatment
target. Future investigation may focus on studying tumors of PHTS
patients and translating aforementioned findings from animal models
to humans. This could achieve greater insight in PHTS pathophys-
iology and help identify possible targets for therapy.
By means of this review, we have demonstrated that signs of
immune dysregulation have been reported consistently in PHTS
patients. Clinical phenomena differ among patients, but three clinical
hallmarks can be identified from current available literature. Firstly,
an increased susceptibility to viral and bacterial infection is observed
[11,12,16,18]. Secondly, an increased frequency of autoimmune
disorders is reported in PHTS patients, ranging from autoimmune
thyroiditis to haemolytic anemia [13,14].
PHTS has previously been characterized as a genetic tumor risk
syndrome with macrocephaly caused by a germline mutation in the
PTEN gene. Literature suggests that immune dysregulation is also a
feature caused by pathogenic germline PTEN mutations. Combined
with the knowledge that the immune system has an instrumental role
in carcinogenesis, immune dysregulation and increased cancer risk
could be considered as two features of PHTS that are not merely co-
occurring but interdependent.
Linking immunological dysregulation to pathological germline
mutations in PTEN and increased cancer risk might have
implications for future treatment of PHTS patients. Uncovering
the ways by which the immune system contributes to carcinogenesis
in PHTS may provide manageable targets for further treatment of this
grave disease.
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